Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer / 中华肿瘤杂志

Objective: To explore the efficacy and safety of real-world eribulin in the treatment of metastatic breast cancer. Methods: From December 2019 to December 2020, patients with advanced breast cancer were selected from Beijing Chaoyang District Sanhuan Cancer Hospital, Shandong Cancer Hospital, Peking University Cancer Hospital, Baotou Cancer Hospital, Shengjing Hospital Affiliated to China Medical University, and Cancer Hospital of Chinese Academy of Medical Sciences. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox regression model was used for multivariate analysis. Results: The median progression-free survival (PFS) of 77 patients was 5 months, the objective response rate (ORR) was 33.8%, and the disease control rate (DCR) was 71.4%. The ORR of patients with triple-negative breast cancer was 23.1%, and the DCR was 57.7%; the ORR of patients with Luminal breast cancer was 40.0%, and the DCR was 77.8%; the ORR of patients with HER-2 overexpression breast cancer was 33.3%, and the DCR was 83.3%. ORR of 50.0% and DCR of 66.7% for patients treated with eribulin as first to second line treatment, ORR of 29.4% and DCR of 76.5% for patients treated with third to fourth line and ORR of 28.6% and DCR of 71.4% for patients treated with five to eleven line. The ORR of patients in the eribulin monotherapy group was 40.0% and the DCR was 66.0%; the ORR of patients in the combination chemotherapy or targeted therapy group was 22.2% and the DCR was 81.5%. Patients with a history of treatment with paclitaxel, docetaxel, or albumin paclitaxel during the adjuvant phase or after recurrent metastasis had an ORR of 32.9% and a DCR of 69.9% when treated with eribulin. The treatment efficacy is an independent prognostic factor affecting patient survival (P<0.001). The main adverse reactions in the whole group of patients were Grade Ⅲ-Ⅳ neutrophil decline [29.9% (23/77)], and other adverse reactions were Grade Ⅲ-Ⅳ fatigue [5.2% (4/77)], Grade Ⅲ-Ⅳ peripheral nerve abnormality [2.6% (2/77)] and Grade Ⅲ-Ⅳ alopecia [2.6% (2/77)]. Conclusions: Eribulin still has good antitumor activity against various molecular subtypes of breast cancer and advanced breast cancer that has failed multiple lines of chemotherapy, and the adverse effects can be controlled, so it has a good clinical application value.

Effect of different treatments of dentin surface on sheer bond strength between different bonding agents and dentin / 华西口腔医学杂志

<p><b>OBJECTIVE</b>To evaluate the effect of Zinc oxide-eugenol cement and Gluma desensitizer on the sheer bond strength of three kinds of dentin bonding agents. The three dentin bonding agents were Zinc phosphate cement, Glass ionomer cement and Super-Bond C&B. To find the theory depending for the using of different protective methods and the selecting of different kinds of dentin bonding agents in prepared abutment teeth.</p><p><b>METHODS</b>The buccal surfaces of ninety freshly extracted human premolars were flattened to expose an adequate area of lower dentin. Followed by wet-grinding on a series of silicon carbide paper from number 320, 400, 600 grit to produce the dentin bonding surface. The teeth roots were embedded in self-curing resin with the crown out of the resin. The embedded ninety teeth were divided randomly into three groups. The group A was control and the dentin surfaces were not treated. The group B was covered with a paste of Zinc oxide-eugenol cement. The group C was covered with Gluma desensitizer. Calculating the sheer strength between three bonding agents and dentin after the two treatments of dentin surface. The results were statistically assessed with SPSS software. Dentin surfaces were observed with scanning electron microscope (SEM).</p><p><b>RESULTS</b>The sheer bond strengths of Zinc phosphate cement had significant decrease (P<0.05), especially the C1 group. The sheer bond strengths of Glass ionomer cement and Super-Bond C&B had no significant difference.</p><p><b>CONCLUSION</b>Zinc oxide-eugenol cement and Gluma desensitizer could reduce the sheer bond strength of Zinc phosphate cement with dentin surface. Zinc oxide-eugenol cement and the Gluma desensitizer could not effect Glass ionomer cement and the Super-Bond C&B with dentin.</p>